AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Merck & Co Inc is buying Pandion Therapeutics, the biotechnology company developing bispecific antibody therapeutics headquartered in Massachusetts. It was said that the pharmaceutical firm is shelling out a total of $1.85 billion in cash to acquire it.
Merck’s target expansion
The acquisition was revealed on Feb. 25 through a joint statement from Merck and Pandion Therapeutics. The deal is also equivalent to a $60 per share deal that amounts to a 134% premium to Pandion’s closing price on Wednesday.
As per Fox Business, Merck & Co Inc. is purchasing the said drug developer to broaden its portfolio of drugs designed for autoimmune diseases. With the deal, the pharmaceutical company that is one of the largest in the world is also set to have Pandion’s major drug candidate called PT101, which is currently undergoing testing for public release.
The drug already completed and passed the phase 1a clinical trial last month for safety and tolerability. It is now in the early stage of the trial involving volunteer patients with autoimmune diseases.
“This acquisition builds upon Merck’s strategy to identify and secure candidates with differentiated and potentially foundational characteristics,” Dr. Dean Y. Li, Merck Research Laboratories president said in a press release. “Pandion has applied its TALON technology to develop a robust pipeline of candidates designed to re-balance the immune response with potential applications across a wide array of autoimmune diseases.”
Merck and Pandion are expected to close the deal before the second half of this year begins. Both companies confirmed this during the announcement this week.
Merck and Pandion’s stocks up after the buyout reveal
The New Jersey-headquartered pharma company is paying more than double Pandion’s current stock price, and the news of this deal drove both Merck and Pandion’s share to shoot up.
Shares of the drug developer closed at $25.63 after the confirmation of the acquisition, while Merck shares increased by 0.3% in premarket trading.
Meanwhile, this was Merck’s latest purchase as it had entered into a number of deals before 2020 closed. One of its major acquisitions was the biotech company VelosBio which was bought for $2.75 billion. It also acquired Oncolmmune, another private firm, for $425 million.
